Clinical Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia.
Clinical Hospital Centre Rijeka, Department of Radiotherapy and Oncology, Rijeka, Croatia.
Anticancer Res. 2020 Apr;40(4):2157-2163. doi: 10.21873/anticanres.14175.
BACKGROUND/AIM: There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear.
We evaluated patients with metastatic melanoma treated with pembrolizumab with the goal of analysing the relationship between a relative change in S100 level at 12 weeks of immunotherapy and survival.
Patients with a relative change in S100 level >145% at 12 weeks of immunotherapy had significantly shorter progression-free (5.1 vs. 18.5 months, p≤0.0001) and overall survival (5.7 vs. 26.3 months, p<0.0001), further confirmed on multivariate analysis with hazard ratio of 32.25 (95% confidence interval=4.78-217.6, p=0.0004) for overall survival.
A relative change in S100 level might be useful as a more precise biomarker of survival for patients with metastatic melanoma treated with pembrolizumab.
背景/目的：接受免疫治疗的转移性黑色素瘤患者缺乏生存质量的生物标志物。虽然基线 S100 水平具有预后价值，但在治疗期间/之后其对生存的作用尚不清楚。
我们评估了接受 pembrolizumab 治疗的转移性黑色素瘤患者，目的是分析免疫治疗 12 周时 S100 水平的相对变化与生存之间的关系。
在免疫治疗 12 周时 S100 水平相对变化>145%的患者无进展生存期（5.1 与 18.5 个月，p≤0.0001）和总生存期（5.7 与 26.3 个月，p<0.0001）显著缩短，多因素分析显示总生存期的危险比为 32.25（95%置信区间为 4.78-217.6，p=0.0004）。
S100 水平的相对变化可能是一种更精确的接受 pembrolizumab 治疗的转移性黑色素瘤患者生存的生物标志物。
